Sironax’s SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)

May 11, 2026
Read More
April 22, 2026

Sironax Announces Abstract on SARM1 Inhibitor SIR2501 Selected for Presentation at 2026 ASCO Annual Meeting

Read More
March 26, 2026

Sironax Appoints Clive Wang to Board of Directors

Read More
March 20, 2026

Sironax Announces Upcoming Poster Presentation on NAMPT Activation

Read More
February 6, 2026

Employees Share Their Pride in Accomplishments at Sironax

Read More
November 6, 2025

Sironax Announces Three Abstracts Selected for Presentation at Neuroscience 2025

Read More
October 22, 2025

Sironax Announces Key Leadership Appointments to Advance Global Drug Discovery and Development

Read More